| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colitis, Ulcerative | 154 | 2024 | 711 | 36.810 |
Why?
|
| Inflammatory Bowel Diseases | 114 | 2024 | 549 | 27.200 |
Why?
|
| Crohn Disease | 115 | 2023 | 730 | 24.850 |
Why?
|
| Gastrointestinal Agents | 28 | 2022 | 161 | 8.280 |
Why?
|
| Antibodies, Monoclonal, Humanized | 37 | 2023 | 930 | 7.350 |
Why?
|
| Anti-Inflammatory Agents | 27 | 2021 | 339 | 7.140 |
Why?
|
| Gastroenterology | 23 | 2023 | 134 | 6.840 |
Why?
|
| Colonoscopy | 43 | 2023 | 264 | 6.820 |
Why?
|
| Colonic Pouches | 17 | 2023 | 67 | 6.360 |
Why?
|
| Proctocolectomy, Restorative | 15 | 2023 | 87 | 5.680 |
Why?
|
| Colorectal Neoplasms | 33 | 2023 | 938 | 5.360 |
Why?
|
| Colitis | 12 | 2022 | 239 | 5.010 |
Why?
|
| Remission Induction | 46 | 2024 | 722 | 4.940 |
Why?
|
| Humans | 388 | 2024 | 86643 | 4.610 |
Why?
|
| Immunosuppressive Agents | 24 | 2023 | 977 | 4.300 |
Why?
|
| Tumor Necrosis Factor-alpha | 24 | 2021 | 683 | 4.170 |
Why?
|
| Mesalamine | 16 | 2021 | 88 | 3.800 |
Why?
|
| Feces | 19 | 2023 | 319 | 3.730 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 14 | 2021 | 243 | 3.670 |
Why?
|
| Piperidines | 13 | 2023 | 181 | 3.620 |
Why?
|
| Adalimumab | 17 | 2023 | 80 | 3.530 |
Why?
|
| Adult | 162 | 2023 | 25648 | 3.390 |
Why?
|
| Pneumonia, Viral | 11 | 2020 | 316 | 3.350 |
Why?
|
| Coronavirus Infections | 11 | 2020 | 301 | 3.340 |
Why?
|
| Severity of Illness Index | 38 | 2024 | 1801 | 3.130 |
Why?
|
| Pyrimidines | 12 | 2023 | 370 | 3.120 |
Why?
|
| Colectomy | 15 | 2023 | 167 | 3.090 |
Why?
|
| Disease Management | 12 | 2021 | 327 | 2.940 |
Why?
|
| Retrospective Studies | 77 | 2023 | 8489 | 2.910 |
Why?
|
| Intestinal Mucosa | 24 | 2023 | 797 | 2.880 |
Why?
|
| Male | 175 | 2023 | 40965 | 2.870 |
Why?
|
| Middle Aged | 134 | 2023 | 25028 | 2.730 |
Why?
|
| Female | 181 | 2023 | 44532 | 2.700 |
Why?
|
| Pouchitis | 9 | 2023 | 44 | 2.670 |
Why?
|
| Pyrroles | 10 | 2023 | 184 | 2.600 |
Why?
|
| Young Adult | 67 | 2023 | 5976 | 2.460 |
Why?
|
| Treatment Outcome | 65 | 2024 | 7993 | 2.450 |
Why?
|
| Infliximab | 15 | 2023 | 151 | 2.410 |
Why?
|
| Pandemics | 13 | 2021 | 740 | 2.400 |
Why?
|
| Biological Products | 12 | 2023 | 143 | 2.370 |
Why?
|
| Ustekinumab | 7 | 2023 | 47 | 2.330 |
Why?
|
| Clostridium Infections | 10 | 2023 | 125 | 2.310 |
Why?
|
| Colonic Neoplasms | 13 | 2019 | 556 | 2.300 |
Why?
|
| Practice Guidelines as Topic | 14 | 2020 | 1036 | 2.270 |
Why?
|
| Azathioprine | 7 | 2021 | 125 | 2.180 |
Why?
|
| Inflammation | 19 | 2023 | 920 | 2.140 |
Why?
|
| Drug Monitoring | 8 | 2022 | 118 | 2.130 |
Why?
|
| Ileum | 12 | 2022 | 159 | 2.120 |
Why?
|
| Betacoronavirus | 10 | 2020 | 258 | 2.050 |
Why?
|
| Precancerous Conditions | 10 | 2016 | 196 | 2.030 |
Why?
|
| Physician-Patient Relations | 12 | 2021 | 610 | 2.000 |
Why?
|
| Endoscopy, Gastrointestinal | 10 | 2023 | 153 | 1.970 |
Why?
|
| Antibodies, Monoclonal | 14 | 2022 | 1376 | 1.940 |
Why?
|
| Gastroenterologists | 7 | 2023 | 30 | 1.890 |
Why?
|
| Indans | 5 | 2024 | 31 | 1.850 |
Why?
|
| Protein Kinase Inhibitors | 6 | 2021 | 589 | 1.830 |
Why?
|
| Oxadiazoles | 5 | 2024 | 46 | 1.820 |
Why?
|
| Hospitalization | 15 | 2022 | 849 | 1.780 |
Why?
|
| Maintenance Chemotherapy | 12 | 2021 | 76 | 1.770 |
Why?
|
| Quality of Life | 24 | 2023 | 1585 | 1.750 |
Why?
|
| Induction Chemotherapy | 8 | 2022 | 147 | 1.740 |
Why?
|
| Colon | 17 | 2021 | 496 | 1.730 |
Why?
|
| Biopsy | 11 | 2023 | 1163 | 1.720 |
Why?
|
| Cholangitis, Sclerosing | 5 | 2023 | 52 | 1.710 |
Why?
|
| Diarrhea | 4 | 2020 | 182 | 1.620 |
Why?
|
| Microbiota | 11 | 2023 | 381 | 1.600 |
Why?
|
| Biological Therapy | 6 | 2022 | 45 | 1.550 |
Why?
|
| Adolescent | 47 | 2023 | 8981 | 1.530 |
Why?
|
| Wound Healing | 8 | 2021 | 344 | 1.530 |
Why?
|
| Leukocyte L1 Antigen Complex | 10 | 2023 | 39 | 1.510 |
Why?
|
| Immunologic Factors | 6 | 2023 | 170 | 1.490 |
Why?
|
| Endoscopy | 14 | 2023 | 332 | 1.460 |
Why?
|
| Cyclosporine | 6 | 2022 | 234 | 1.460 |
Why?
|
| Budesonide | 4 | 2019 | 45 | 1.440 |
Why?
|
| Clinical Trials as Topic | 10 | 2023 | 1169 | 1.440 |
Why?
|
| United States | 42 | 2023 | 6672 | 1.440 |
Why?
|
| Risk Factors | 40 | 2023 | 5417 | 1.430 |
Why?
|
| Transplantation | 3 | 2014 | 39 | 1.420 |
Why?
|
| Aged | 66 | 2023 | 18415 | 1.410 |
Why?
|
| Resuscitation Orders | 3 | 2021 | 62 | 1.400 |
Why?
|
| Anti-Bacterial Agents | 8 | 2021 | 746 | 1.400 |
Why?
|
| Calcineurin Inhibitors | 3 | 2021 | 54 | 1.390 |
Why?
|
| Fecal Microbiota Transplantation | 8 | 2023 | 62 | 1.370 |
Why?
|
| Arthritis, Rheumatoid | 3 | 2022 | 166 | 1.370 |
Why?
|
| Adenocarcinoma | 7 | 2019 | 1169 | 1.320 |
Why?
|
| Research Subjects | 2 | 2021 | 73 | 1.310 |
Why?
|
| Secondary Prevention | 5 | 2021 | 162 | 1.290 |
Why?
|
| Mercaptopurine | 4 | 2018 | 53 | 1.290 |
Why?
|
| Prospective Studies | 24 | 2023 | 4213 | 1.280 |
Why?
|
| Janus Kinase Inhibitors | 4 | 2023 | 19 | 1.270 |
Why?
|
| Intestinal Obstruction | 5 | 2016 | 88 | 1.270 |
Why?
|
| Adrenal Cortex Hormones | 5 | 2024 | 263 | 1.270 |
Why?
|
| Follow-Up Studies | 25 | 2023 | 3640 | 1.240 |
Why?
|
| Drug Therapy, Combination | 9 | 2021 | 894 | 1.230 |
Why?
|
| Glucocorticoids | 6 | 2020 | 352 | 1.230 |
Why?
|
| Recurrence | 18 | 2023 | 1139 | 1.210 |
Why?
|
| Infection Control | 4 | 2020 | 115 | 1.210 |
Why?
|
| Colonic Polyps | 9 | 2018 | 126 | 1.170 |
Why?
|
| Psoriasis | 2 | 2022 | 240 | 1.160 |
Why?
|
| Measles | 2 | 2016 | 15 | 1.140 |
Why?
|
| Postoperative Complications | 10 | 2022 | 2207 | 1.140 |
Why?
|
| Capsule Endoscopy | 6 | 2020 | 33 | 1.120 |
Why?
|
| Fellowships and Scholarships | 2 | 2019 | 108 | 1.120 |
Why?
|
| Methotrexate | 2 | 2018 | 249 | 1.120 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 5 | 2022 | 199 | 1.120 |
Why?
|
| Digestive System Surgical Procedures | 6 | 2021 | 120 | 1.120 |
Why?
|
| Health Services Accessibility | 3 | 2021 | 394 | 1.090 |
Why?
|
| Guanine Nucleotides | 2 | 2018 | 14 | 1.080 |
Why?
|
| Intestine, Small | 6 | 2020 | 303 | 1.070 |
Why?
|
| Thionucleotides | 2 | 2018 | 56 | 1.060 |
Why?
|
| Prognosis | 27 | 2023 | 3679 | 1.040 |
Why?
|
| Chronic Disease | 13 | 2023 | 971 | 1.030 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2020 | 138 | 1.010 |
Why?
|
| Patient Satisfaction | 4 | 2021 | 455 | 1.010 |
Why?
|
| Steroids | 4 | 2022 | 177 | 1.000 |
Why?
|
| Gastrointestinal Hemorrhage | 3 | 2017 | 229 | 0.980 |
Why?
|
| Organometallic Compounds | 2 | 2020 | 132 | 0.970 |
Why?
|
| Quality of Health Care | 4 | 2021 | 380 | 0.970 |
Why?
|
| C-Reactive Protein | 9 | 2023 | 190 | 0.950 |
Why?
|
| Disease Progression | 19 | 2023 | 1531 | 0.940 |
Why?
|
| Symptom Assessment | 2 | 2021 | 65 | 0.940 |
Why?
|
| Rectum | 5 | 2023 | 146 | 0.940 |
Why?
|
| Case-Control Studies | 13 | 2021 | 1805 | 0.920 |
Why?
|
| Irritable Bowel Syndrome | 2 | 2020 | 45 | 0.910 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2023 | 865 | 0.900 |
Why?
|
| Communication | 4 | 2021 | 441 | 0.890 |
Why?
|
| Aged, 80 and over | 24 | 2023 | 6509 | 0.880 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2021 | 238 | 0.880 |
Why?
|
| Proctitis | 4 | 2022 | 12 | 0.870 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2022 | 10 | 0.870 |
Why?
|
| Ileal Neoplasms | 1 | 2022 | 9 | 0.870 |
Why?
|
| Endoscopic Mucosal Resection | 1 | 2022 | 21 | 0.860 |
Why?
|
| Colonography, Computed Tomographic | 6 | 2010 | 81 | 0.840 |
Why?
|
| Incidence | 17 | 2023 | 1577 | 0.830 |
Why?
|
| Health Care Costs | 6 | 2021 | 238 | 0.830 |
Why?
|
| Intestinal Neoplasms | 1 | 2022 | 56 | 0.820 |
Why?
|
| Physicians | 4 | 2021 | 673 | 0.820 |
Why?
|
| Clinical Competence | 2 | 2019 | 751 | 0.820 |
Why?
|
| Insurance, Health | 2 | 2020 | 160 | 0.810 |
Why?
|
| Tertiary Care Centers | 3 | 2019 | 94 | 0.800 |
Why?
|
| Arthritis, Psoriatic | 2 | 2022 | 32 | 0.800 |
Why?
|
| Double-Blind Method | 18 | 2023 | 1823 | 0.800 |
Why?
|
| Sleep Wake Disorders | 2 | 2020 | 115 | 0.790 |
Why?
|
| Tertiary Healthcare | 1 | 2020 | 4 | 0.780 |
Why?
|
| Wearable Electronic Devices | 1 | 2021 | 23 | 0.780 |
Why?
|
| Multiple Chronic Conditions | 1 | 2020 | 5 | 0.780 |
Why?
|
| Case Management | 1 | 2020 | 24 | 0.770 |
Why?
|
| Smoking | 5 | 2020 | 609 | 0.770 |
Why?
|
| Bismuth | 1 | 2020 | 8 | 0.770 |
Why?
|
| Basic Reproduction Number | 1 | 2020 | 6 | 0.760 |
Why?
|
| Antidiarrheals | 1 | 2020 | 14 | 0.760 |
Why?
|
| Patellar Dislocation | 1 | 2020 | 11 | 0.760 |
Why?
|
| Time Factors | 18 | 2021 | 5210 | 0.760 |
Why?
|
| Salicylates | 1 | 2020 | 25 | 0.750 |
Why?
|
| Intestinal Fistula | 3 | 2021 | 30 | 0.750 |
Why?
|
| Anastomosis, Surgical | 8 | 2022 | 267 | 0.750 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2020 | 19 | 0.750 |
Why?
|
| Biosensing Techniques | 1 | 2021 | 68 | 0.740 |
Why?
|
| Cough | 1 | 2020 | 54 | 0.740 |
Why?
|
| Patient Selection | 2 | 2021 | 685 | 0.740 |
Why?
|
| Vancomycin | 2 | 2020 | 72 | 0.740 |
Why?
|
| Population Density | 1 | 2020 | 60 | 0.730 |
Why?
|
| Health Care Rationing | 1 | 2020 | 83 | 0.730 |
Why?
|
| Mucous Membrane | 3 | 2023 | 83 | 0.730 |
Why?
|
| Biomarkers | 13 | 2022 | 1718 | 0.720 |
Why?
|
| Attitude to Health | 4 | 2017 | 220 | 0.720 |
Why?
|
| Metronidazole | 1 | 2019 | 26 | 0.720 |
Why?
|
| History, 20th Century | 7 | 2014 | 312 | 0.710 |
Why?
|
| Joint Instability | 1 | 2020 | 81 | 0.710 |
Why?
|
| Drug Administration Schedule | 7 | 2019 | 916 | 0.700 |
Why?
|
| Drug Resistance | 2 | 2019 | 256 | 0.700 |
Why?
|
| Knee Joint | 1 | 2020 | 168 | 0.700 |
Why?
|
| Medical Marijuana | 1 | 2019 | 5 | 0.690 |
Why?
|
| Polyethylene Glycols | 4 | 2018 | 363 | 0.690 |
Why?
|
| Gastrointestinal Tract | 3 | 2017 | 191 | 0.680 |
Why?
|
| Temperature | 1 | 2020 | 396 | 0.680 |
Why?
|
| Government Regulation | 1 | 2019 | 49 | 0.680 |
Why?
|
| Radiography, Abdominal | 1 | 2019 | 71 | 0.670 |
Why?
|
| Genetic Testing | 3 | 2009 | 535 | 0.670 |
Why?
|
| Renal Nutcracker Syndrome | 1 | 2018 | 2 | 0.660 |
Why?
|
| Curriculum | 2 | 2021 | 539 | 0.660 |
Why?
|
| Nephrotic Syndrome | 1 | 2018 | 33 | 0.650 |
Why?
|
| Intestines | 7 | 2024 | 411 | 0.640 |
Why?
|
| Practice Patterns, Physicians' | 6 | 2021 | 582 | 0.640 |
Why?
|
| Drug Approval | 1 | 2018 | 62 | 0.640 |
Why?
|
| Hematuria | 1 | 2018 | 49 | 0.640 |
Why?
|
| Risk Assessment | 15 | 2021 | 2261 | 0.640 |
Why?
|
| Spondylitis, Ankylosing | 2 | 2017 | 24 | 0.630 |
Why?
|
| Antibodies, Viral | 2 | 2016 | 293 | 0.630 |
Why?
|
| Mental Recall | 2 | 2011 | 159 | 0.630 |
Why?
|
| Predictive Value of Tests | 8 | 2021 | 1673 | 0.620 |
Why?
|
| Cohort Studies | 14 | 2021 | 2767 | 0.620 |
Why?
|
| Colonoscopes | 2 | 2015 | 11 | 0.610 |
Why?
|
| Quality Improvement | 2 | 2021 | 428 | 0.610 |
Why?
|
| Celiac Disease | 1 | 2020 | 203 | 0.600 |
Why?
|
| Early Detection of Cancer | 3 | 2019 | 394 | 0.600 |
Why?
|
| Digestive System Diseases | 1 | 2017 | 18 | 0.600 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2017 | 72 | 0.600 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2018 | 236 | 0.590 |
Why?
|
| Ostomy | 2 | 2020 | 15 | 0.590 |
Why?
|
| Proctocolitis | 2 | 2016 | 3 | 0.590 |
Why?
|
| Histiocytosis, Sinus | 1 | 2016 | 14 | 0.580 |
Why?
|
| Morbillivirus | 1 | 2016 | 2 | 0.580 |
Why?
|
| Whooping Cough | 1 | 2016 | 3 | 0.580 |
Why?
|
| Bordetella pertussis | 1 | 2016 | 15 | 0.580 |
Why?
|
| Mass Screening | 7 | 2020 | 618 | 0.570 |
Why?
|
| Zinc | 1 | 2017 | 91 | 0.570 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2016 | 7 | 0.570 |
Why?
|
| Deception | 1 | 2016 | 20 | 0.560 |
Why?
|
| Positron-Emission Tomography | 3 | 2020 | 329 | 0.560 |
Why?
|
| Liver Diseases | 1 | 2018 | 238 | 0.560 |
Why?
|
| Patient Dropouts | 1 | 2016 | 28 | 0.560 |
Why?
|
| Antibodies, Bacterial | 1 | 2016 | 95 | 0.560 |
Why?
|
| Surveys and Questionnaires | 13 | 2022 | 2501 | 0.560 |
Why?
|
| Cost of Illness | 5 | 2020 | 150 | 0.550 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2016 | 86 | 0.550 |
Why?
|
| Antibodies | 2 | 2017 | 350 | 0.540 |
Why?
|
| Immunoglobulin Fab Fragments | 3 | 2014 | 81 | 0.540 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 369 | 0.530 |
Why?
|
| Mesentery | 1 | 2015 | 45 | 0.530 |
Why?
|
| History, 21st Century | 5 | 2014 | 175 | 0.530 |
Why?
|
| Problem-Based Learning | 1 | 2015 | 25 | 0.520 |
Why?
|
| Diverticulum | 1 | 2015 | 44 | 0.520 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2020 | 3362 | 0.520 |
Why?
|
| Allopurinol | 2 | 2013 | 80 | 0.520 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 3 | 2023 | 26 | 0.520 |
Why?
|
| Antirheumatic Agents | 3 | 2021 | 54 | 0.510 |
Why?
|
| Liver | 2 | 2018 | 1230 | 0.510 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2014 | 19 | 0.510 |
Why?
|
| Ambulatory Care | 3 | 2021 | 181 | 0.500 |
Why?
|
| Cholagogues and Choleretics | 1 | 2014 | 10 | 0.500 |
Why?
|
| Neoplasms, Second Primary | 4 | 2012 | 252 | 0.500 |
Why?
|
| Child | 15 | 2022 | 6927 | 0.490 |
Why?
|
| Adenomatous Polyposis Coli | 3 | 2022 | 39 | 0.490 |
Why?
|
| Carcinoma | 2 | 2014 | 436 | 0.490 |
Why?
|
| Ultrasonography | 4 | 2024 | 695 | 0.490 |
Why?
|
| Ileitis | 1 | 2014 | 7 | 0.490 |
Why?
|
| Patient-Centered Care | 1 | 2016 | 203 | 0.480 |
Why?
|
| Administration, Oral | 6 | 2021 | 684 | 0.480 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2020 | 241 | 0.480 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2013 | 31 | 0.470 |
Why?
|
| Neuroendocrine Tumors | 1 | 2015 | 105 | 0.460 |
Why?
|
| Societies, Medical | 4 | 2021 | 572 | 0.460 |
Why?
|
| Drug Prescriptions | 3 | 2020 | 141 | 0.460 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2016 | 1961 | 0.460 |
Why?
|
| Gastric Mucosa | 1 | 2013 | 66 | 0.450 |
Why?
|
| Enteritis | 1 | 2013 | 21 | 0.450 |
Why?
|
| Metagenome | 1 | 2013 | 102 | 0.440 |
Why?
|
| Gastritis | 1 | 2013 | 32 | 0.440 |
Why?
|
| Referral and Consultation | 3 | 2023 | 328 | 0.440 |
Why?
|
| Opportunistic Infections | 2 | 2023 | 59 | 0.430 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2012 | 52 | 0.430 |
Why?
|
| Contrast Media | 5 | 2019 | 1078 | 0.420 |
Why?
|
| Perception | 1 | 2013 | 168 | 0.420 |
Why?
|
| Hyperplasia | 2 | 2022 | 148 | 0.420 |
Why?
|
| Periodicals as Topic | 1 | 2014 | 168 | 0.400 |
Why?
|
| Logistic Models | 7 | 2018 | 1186 | 0.400 |
Why?
|
| Abdominal Pain | 6 | 2023 | 137 | 0.400 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2014 | 235 | 0.400 |
Why?
|
| Hematologic Diseases | 1 | 2011 | 79 | 0.400 |
Why?
|
| Evidence-Based Practice | 1 | 2011 | 45 | 0.400 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2010 | 427 | 0.400 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2009 | 109 | 0.400 |
Why?
|
| Malnutrition | 1 | 2011 | 34 | 0.400 |
Why?
|
| Attitude | 1 | 2012 | 127 | 0.390 |
Why?
|
| Population Surveillance | 7 | 2016 | 219 | 0.390 |
Why?
|
| Medication Adherence | 4 | 2019 | 129 | 0.390 |
Why?
|
| Length of Stay | 3 | 2021 | 702 | 0.390 |
Why?
|
| Smoking Cessation | 2 | 2012 | 230 | 0.390 |
Why?
|
| Proportional Hazards Models | 5 | 2020 | 859 | 0.390 |
Why?
|
| Rectal Neoplasms | 2 | 2009 | 116 | 0.380 |
Why?
|
| Chicago | 8 | 2018 | 1379 | 0.380 |
Why?
|
| Appendix | 1 | 2010 | 31 | 0.380 |
Why?
|
| Sulfasalazine | 2 | 2007 | 34 | 0.370 |
Why?
|
| Longitudinal Studies | 6 | 2020 | 1019 | 0.370 |
Why?
|
| Family | 2 | 2009 | 311 | 0.370 |
Why?
|
| Natalizumab | 3 | 2015 | 21 | 0.370 |
Why?
|
| Odds Ratio | 4 | 2021 | 678 | 0.360 |
Why?
|
| Sick Role | 1 | 2009 | 13 | 0.360 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2013 | 508 | 0.360 |
Why?
|
| Prefrontal Cortex | 1 | 2011 | 129 | 0.360 |
Why?
|
| Aminosalicylic Acids | 2 | 2006 | 42 | 0.360 |
Why?
|
| Biosimilar Pharmaceuticals | 2 | 2020 | 20 | 0.360 |
Why?
|
| Anastomotic Leak | 3 | 2021 | 96 | 0.360 |
Why?
|
| Pharmacogenetics | 3 | 2019 | 434 | 0.350 |
Why?
|
| Global Health | 2 | 2021 | 193 | 0.350 |
Why?
|
| Consensus | 8 | 2023 | 335 | 0.350 |
Why?
|
| Radiotherapy | 3 | 2012 | 328 | 0.350 |
Why?
|
| Reproducibility of Results | 10 | 2023 | 2705 | 0.350 |
Why?
|
| Sarcoma, Myeloid | 1 | 2009 | 15 | 0.340 |
Why?
|
| Mandibular Neoplasms | 1 | 2009 | 24 | 0.340 |
Why?
|
| Focus Groups | 1 | 2009 | 155 | 0.340 |
Why?
|
| Insurance, Health, Reimbursement | 2 | 2020 | 59 | 0.340 |
Why?
|
| Memory | 1 | 2011 | 225 | 0.340 |
Why?
|
| Colonic Diseases | 2 | 2021 | 65 | 0.340 |
Why?
|
| Immunocompromised Host | 3 | 2020 | 140 | 0.330 |
Why?
|
| Intestine, Large | 1 | 2008 | 16 | 0.330 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2011 | 294 | 0.330 |
Why?
|
| Medical Records | 2 | 2017 | 119 | 0.330 |
Why?
|
| Databases, Factual | 5 | 2019 | 814 | 0.320 |
Why?
|
| Corynebacterium Infections | 1 | 2008 | 3 | 0.320 |
Why?
|
| Corynebacterium | 1 | 2008 | 9 | 0.320 |
Why?
|
| Patients | 1 | 2009 | 100 | 0.320 |
Why?
|
| Radiopharmaceuticals | 1 | 2009 | 180 | 0.320 |
Why?
|
| Registries | 4 | 2020 | 702 | 0.320 |
Why?
|
| Certolizumab Pegol | 4 | 2016 | 19 | 0.310 |
Why?
|
| Reinforcement, Verbal | 1 | 2007 | 5 | 0.310 |
Why?
|
| Professional Practice | 1 | 2008 | 46 | 0.310 |
Why?
|
| Brain Mapping | 1 | 2011 | 548 | 0.310 |
Why?
|
| Cytomegalovirus Infections | 2 | 2022 | 144 | 0.310 |
Why?
|
| Vitamin D Deficiency | 2 | 2021 | 103 | 0.310 |
Why?
|
| Professional Competence | 1 | 2008 | 68 | 0.300 |
Why?
|
| Mammaplasty | 2 | 2020 | 107 | 0.300 |
Why?
|
| Leukemic Infiltration | 1 | 2007 | 14 | 0.300 |
Why?
|
| Histocytochemistry | 3 | 2017 | 130 | 0.300 |
Why?
|
| Aspirin | 2 | 2021 | 156 | 0.300 |
Why?
|
| Urologic Neoplasms | 1 | 2008 | 77 | 0.300 |
Why?
|
| Health Expenditures | 2 | 2020 | 86 | 0.300 |
Why?
|
| Gastrointestinal Microbiome | 4 | 2023 | 455 | 0.300 |
Why?
|
| Genes, p53 | 1 | 2007 | 109 | 0.300 |
Why?
|
| Sensitivity and Specificity | 11 | 2018 | 1991 | 0.300 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 999 | 0.300 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2007 | 21 | 0.300 |
Why?
|
| Insurance Claim Review | 3 | 2018 | 41 | 0.300 |
Why?
|
| Adenoma | 3 | 2015 | 235 | 0.290 |
Why?
|
| Interprofessional Relations | 2 | 2008 | 121 | 0.290 |
Why?
|
| Patient Acuity | 3 | 2021 | 32 | 0.290 |
Why?
|
| Cathartics | 1 | 2006 | 27 | 0.290 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2020 | 860 | 0.290 |
Why?
|
| Citric Acid | 1 | 2006 | 38 | 0.290 |
Why?
|
| Disclosure | 1 | 2007 | 108 | 0.290 |
Why?
|
| Dietary Fiber | 1 | 2006 | 43 | 0.290 |
Why?
|
| MicroRNAs | 3 | 2017 | 534 | 0.280 |
Why?
|
| Genetic Counseling | 1 | 2006 | 100 | 0.280 |
Why?
|
| Clinical Laboratory Techniques | 3 | 2020 | 73 | 0.280 |
Why?
|
| Infusions, Intravenous | 2 | 2020 | 429 | 0.280 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2017 | 1197 | 0.280 |
Why?
|
| Biomedical Research | 2 | 2021 | 376 | 0.280 |
Why?
|
| Prevalence | 8 | 2021 | 1239 | 0.280 |
Why?
|
| Phenotype | 3 | 2022 | 2378 | 0.280 |
Why?
|
| International Cooperation | 3 | 2021 | 127 | 0.270 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2009 | 2271 | 0.270 |
Why?
|
| Propensity Score | 3 | 2021 | 136 | 0.270 |
Why?
|
| Diagnosis, Differential | 6 | 2016 | 1565 | 0.270 |
Why?
|
| Ileal Diseases | 3 | 2019 | 25 | 0.270 |
Why?
|
| Mesenteric Veins | 1 | 2005 | 34 | 0.260 |
Why?
|
| Constriction, Pathologic | 4 | 2021 | 213 | 0.260 |
Why?
|
| Algorithms | 5 | 2011 | 1830 | 0.250 |
Why?
|
| Symptom Flare Up | 2 | 2021 | 11 | 0.250 |
Why?
|
| Age Factors | 7 | 2021 | 1851 | 0.250 |
Why?
|
| Delayed-Action Preparations | 2 | 2017 | 116 | 0.250 |
Why?
|
| Laparoscopy | 1 | 2011 | 754 | 0.250 |
Why?
|
| Sepsis | 1 | 2008 | 306 | 0.240 |
Why?
|
| Diagnostic Errors | 1 | 2005 | 160 | 0.240 |
Why?
|
| Endpoint Determination | 2 | 2021 | 60 | 0.240 |
Why?
|
| Pregnancy Complications | 2 | 2020 | 336 | 0.240 |
Why?
|
| Documentation | 3 | 2023 | 98 | 0.240 |
Why?
|
| Placebos | 2 | 2021 | 218 | 0.240 |
Why?
|
| Observational Studies as Topic | 1 | 2023 | 48 | 0.240 |
Why?
|
| Blood Sedimentation | 2 | 2020 | 13 | 0.230 |
Why?
|
| Venous Thrombosis | 2 | 2011 | 243 | 0.230 |
Why?
|
| Health Services | 2 | 2021 | 55 | 0.230 |
Why?
|
| Metagenomics | 3 | 2023 | 83 | 0.230 |
Why?
|
| Research Design | 3 | 2023 | 594 | 0.230 |
Why?
|
| Europe | 2 | 2021 | 309 | 0.230 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2021 | 172 | 0.230 |
Why?
|
| Statistics, Nonparametric | 2 | 2017 | 307 | 0.230 |
Why?
|
| Ulcer | 2 | 2022 | 36 | 0.230 |
Why?
|
| Inpatients | 3 | 2021 | 297 | 0.220 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2005 | 379 | 0.220 |
Why?
|
| Child, Preschool | 5 | 2020 | 3612 | 0.220 |
Why?
|
| Patient Care Team | 2 | 2020 | 280 | 0.220 |
Why?
|
| Academic Medical Centers | 2 | 2020 | 379 | 0.220 |
Why?
|
| Cost-Benefit Analysis | 3 | 2021 | 454 | 0.220 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2009 | 763 | 0.220 |
Why?
|
| Immunohistochemistry | 3 | 2016 | 1753 | 0.220 |
Why?
|
| Enterocolitis | 1 | 2022 | 12 | 0.220 |
Why?
|
| Ileostomy | 2 | 2019 | 30 | 0.210 |
Why?
|
| Health Care Surveys | 3 | 2021 | 278 | 0.210 |
Why?
|
| Treatment Failure | 2 | 2019 | 285 | 0.210 |
Why?
|
| Breast Implants | 2 | 2020 | 23 | 0.210 |
Why?
|
| Clinical Decision-Making | 3 | 2021 | 257 | 0.210 |
Why?
|
| Interleukin-23 | 1 | 2022 | 54 | 0.210 |
Why?
|
| Compliance | 1 | 2021 | 23 | 0.210 |
Why?
|
| Committee Membership | 1 | 2021 | 4 | 0.210 |
Why?
|
| Interleukin-12 | 1 | 2022 | 108 | 0.200 |
Why?
|
| Internationality | 1 | 2021 | 69 | 0.200 |
Why?
|
| Marketing | 1 | 2021 | 23 | 0.200 |
Why?
|
| Control Groups | 1 | 2021 | 15 | 0.200 |
Why?
|
| Bibliometrics | 1 | 2021 | 37 | 0.200 |
Why?
|
| Career Mobility | 1 | 2021 | 31 | 0.200 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2012 | 106 | 0.200 |
Why?
|
| Hydroxychloroquine | 1 | 2021 | 10 | 0.200 |
Why?
|
| Azithromycin | 1 | 2021 | 13 | 0.200 |
Why?
|
| North America | 1 | 2021 | 180 | 0.200 |
Why?
|
| Free Tissue Flaps | 2 | 2020 | 49 | 0.200 |
Why?
|
| Th17 Cells | 2 | 2019 | 80 | 0.200 |
Why?
|
| Guidelines as Topic | 2 | 2021 | 162 | 0.200 |
Why?
|
| Arthralgia | 2 | 2019 | 36 | 0.200 |
Why?
|
| Acute Disease | 2 | 2021 | 826 | 0.200 |
Why?
|
| Societies, Scientific | 1 | 2021 | 44 | 0.200 |
Why?
|
| Deprescriptions | 1 | 2021 | 5 | 0.200 |
Why?
|
| Congresses as Topic | 2 | 2020 | 116 | 0.200 |
Why?
|
| Long QT Syndrome | 1 | 2021 | 34 | 0.200 |
Why?
|
| Pressure | 1 | 2021 | 165 | 0.200 |
Why?
|
| Hospital Restructuring | 1 | 2020 | 3 | 0.190 |
Why?
|
| Cardiac Electrophysiology | 1 | 2020 | 4 | 0.190 |
Why?
|
| Self Report | 1 | 2022 | 288 | 0.190 |
Why?
|
| Bacteria | 3 | 2023 | 447 | 0.190 |
Why?
|
| Intention to Treat Analysis | 2 | 2018 | 72 | 0.190 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 298 | 0.190 |
Why?
|
| Ethics, Medical | 2 | 2021 | 306 | 0.190 |
Why?
|
| Information Dissemination | 1 | 2021 | 103 | 0.190 |
Why?
|
| Infant | 5 | 2020 | 3046 | 0.190 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 176 | 0.190 |
Why?
|
| Decision Trees | 1 | 2020 | 63 | 0.190 |
Why?
|
| Lymphopenia | 1 | 2020 | 28 | 0.190 |
Why?
|
| Markov Chains | 1 | 2021 | 125 | 0.190 |
Why?
|
| Survivors | 2 | 2012 | 226 | 0.190 |
Why?
|
| Patient Care Management | 1 | 2020 | 31 | 0.190 |
Why?
|
| Evaluation Studies as Topic | 1 | 2020 | 274 | 0.190 |
Why?
|
| Methylprednisolone | 1 | 2020 | 66 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2020 | 2601 | 0.190 |
Why?
|
| Epidemiological Monitoring | 1 | 2020 | 39 | 0.190 |
Why?
|
| Retreatment | 2 | 2017 | 107 | 0.190 |
Why?
|
| Endoscopy, Digestive System | 2 | 2018 | 65 | 0.190 |
Why?
|
| Prostatic Neoplasms | 2 | 2009 | 1721 | 0.190 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2020 | 19 | 0.190 |
Why?
|
| Surgical Stomas | 1 | 2020 | 22 | 0.180 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2021 | 138 | 0.180 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 32 | 0.180 |
Why?
|
| Carcinogenesis | 2 | 2019 | 195 | 0.180 |
Why?
|
| Safety Management | 1 | 2020 | 56 | 0.180 |
Why?
|
| Drug Costs | 2 | 2019 | 62 | 0.180 |
Why?
|
| Infant, Newborn | 4 | 2020 | 2379 | 0.180 |
Why?
|
| Emergency Service, Hospital | 2 | 2021 | 484 | 0.180 |
Why?
|
| Triage | 1 | 2020 | 108 | 0.180 |
Why?
|
| Pharmacogenomic Testing | 2 | 2019 | 97 | 0.180 |
Why?
|
| Social Media | 1 | 2021 | 79 | 0.180 |
Why?
|
| Leadership | 1 | 2021 | 134 | 0.180 |
Why?
|
| Biomarkers, Tumor | 6 | 2018 | 1464 | 0.180 |
Why?
|
| Anxiety | 2 | 2021 | 287 | 0.180 |
Why?
|
| Point-of-Care Systems | 2 | 2019 | 141 | 0.180 |
Why?
|
| Reoperation | 2 | 2020 | 597 | 0.180 |
Why?
|
| Universities | 1 | 2020 | 135 | 0.180 |
Why?
|
| Abortion, Spontaneous | 1 | 2020 | 66 | 0.180 |
Why?
|
| User-Computer Interface | 1 | 2001 | 185 | 0.180 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 57 | 0.180 |
Why?
|
| Medication Therapy Management | 1 | 2019 | 16 | 0.180 |
Why?
|
| Influenza Vaccines | 1 | 2020 | 142 | 0.180 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2017 | 103 | 0.180 |
Why?
|
| Microsurgery | 1 | 2020 | 84 | 0.180 |
Why?
|
| Anemia | 1 | 2020 | 128 | 0.170 |
Why?
|
| Fibrinolytic Agents | 1 | 2021 | 202 | 0.170 |
Why?
|
| Health Status Disparities | 1 | 2021 | 170 | 0.170 |
Why?
|
| Faculty, Medical | 1 | 2021 | 178 | 0.170 |
Why?
|
| Drug Substitution | 1 | 2019 | 25 | 0.170 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2019 | 15 | 0.170 |
Why?
|
| Administration, Rectal | 2 | 2016 | 12 | 0.170 |
Why?
|
| Electrophysiology | 1 | 2020 | 401 | 0.170 |
Why?
|
| Constipation | 1 | 2020 | 63 | 0.170 |
Why?
|
| Neoplasm Grading | 2 | 2018 | 357 | 0.170 |
Why?
|
| Foreign Bodies | 1 | 2020 | 63 | 0.170 |
Why?
|
| Caregivers | 1 | 2020 | 151 | 0.170 |
Why?
|
| Renin-Angiotensin System | 2 | 2019 | 133 | 0.170 |
Why?
|
| European Union | 1 | 2018 | 8 | 0.170 |
Why?
|
| Vaccination | 1 | 2021 | 254 | 0.170 |
Why?
|
| Consent Forms | 1 | 2018 | 11 | 0.170 |
Why?
|
| Government Agencies | 1 | 2018 | 10 | 0.170 |
Why?
|
| Prescription Drugs | 1 | 2019 | 36 | 0.170 |
Why?
|
| Arthritis | 1 | 2019 | 46 | 0.170 |
Why?
|
| Electrocardiography | 1 | 2021 | 478 | 0.170 |
Why?
|
| Immune System Diseases | 1 | 2019 | 26 | 0.170 |
Why?
|
| Health Resources | 1 | 2019 | 76 | 0.160 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2018 | 19 | 0.160 |
Why?
|
| Thrombosis | 1 | 2021 | 296 | 0.160 |
Why?
|
| Renal Veins | 1 | 2018 | 28 | 0.160 |
Why?
|
| Aberrant Crypt Foci | 1 | 2018 | 7 | 0.160 |
Why?
|
| Malpractice | 1 | 2018 | 57 | 0.160 |
Why?
|
| Laxatives | 1 | 2018 | 13 | 0.160 |
Why?
|
| Health Policy | 1 | 2020 | 180 | 0.160 |
Why?
|
| Depression | 2 | 2021 | 473 | 0.160 |
Why?
|
| SEER Program | 2 | 2009 | 190 | 0.160 |
Why?
|
| Vitamin D | 2 | 2021 | 261 | 0.160 |
Why?
|
| United States Food and Drug Administration | 1 | 2018 | 127 | 0.160 |
Why?
|
| Liver Function Tests | 1 | 2018 | 93 | 0.160 |
Why?
|
| Anticarcinogenic Agents | 1 | 2018 | 70 | 0.160 |
Why?
|
| Thrombospondins | 1 | 2017 | 14 | 0.150 |
Why?
|
| Caveolin 1 | 1 | 2017 | 20 | 0.150 |
Why?
|
| Telemedicine | 1 | 2020 | 169 | 0.150 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2021 | 212 | 0.150 |
Why?
|
| Treatment Refusal | 2 | 2008 | 60 | 0.150 |
Why?
|
| Uncertainty | 2 | 2009 | 71 | 0.150 |
Why?
|
| Medical Errors | 1 | 2018 | 115 | 0.150 |
Why?
|
| Influenza, Human | 1 | 2020 | 329 | 0.150 |
Why?
|
| Receptors, Interleukin | 1 | 2017 | 35 | 0.150 |
Why?
|
| Syndrome | 1 | 2018 | 446 | 0.150 |
Why?
|
| Collagen Type I | 1 | 2017 | 62 | 0.150 |
Why?
|
| Medical Order Entry Systems | 1 | 2017 | 25 | 0.150 |
Why?
|
| DNA Mutational Analysis | 2 | 2019 | 526 | 0.150 |
Why?
|
| Up-Regulation | 2 | 2018 | 712 | 0.150 |
Why?
|
| Animals | 11 | 2020 | 26582 | 0.150 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 153 | 0.150 |
Why?
|
| Managed Care Programs | 1 | 2017 | 42 | 0.150 |
Why?
|
| Comorbidity | 4 | 2021 | 943 | 0.150 |
Why?
|
| Cross-Sectional Studies | 3 | 2017 | 1621 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 371 | 0.150 |
Why?
|
| Pertussis Vaccine | 1 | 2016 | 2 | 0.150 |
Why?
|
| Patient Education as Topic | 3 | 2009 | 351 | 0.150 |
Why?
|
| Measles Vaccine | 1 | 2016 | 7 | 0.150 |
Why?
|
| Mental Health | 1 | 2018 | 162 | 0.150 |
Why?
|
| Focal Adhesions | 1 | 2017 | 69 | 0.150 |
Why?
|
| Vena Cava, Inferior | 1 | 2018 | 143 | 0.140 |
Why?
|
| Patient Compliance | 2 | 2008 | 227 | 0.140 |
Why?
|
| Immunization, Secondary | 1 | 2016 | 30 | 0.140 |
Why?
|
| Tacrolimus | 1 | 2018 | 373 | 0.140 |
Why?
|
| Bacteroides | 1 | 2016 | 33 | 0.140 |
Why?
|
| Genetic Markers | 2 | 2014 | 476 | 0.140 |
Why?
|
| Chemoprevention | 3 | 2018 | 91 | 0.140 |
Why?
|
| Mental Disorders | 1 | 2020 | 371 | 0.140 |
Why?
|
| Illinois | 3 | 2019 | 462 | 0.140 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 827 | 0.140 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 1384 | 0.140 |
Why?
|
| Precision Medicine | 2 | 2019 | 395 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2019 | 1313 | 0.140 |
Why?
|
| Gastrointestinal Motility | 1 | 2016 | 25 | 0.140 |
Why?
|
| Image-Guided Biopsy | 1 | 2016 | 66 | 0.140 |
Why?
|
| Renin | 1 | 2016 | 79 | 0.140 |
Why?
|
| Lymphocyte Activation | 1 | 2019 | 728 | 0.140 |
Why?
|
| Sleep | 1 | 2020 | 444 | 0.140 |
Why?
|
| Neoplasms | 4 | 2019 | 2898 | 0.140 |
Why?
|
| Risk | 2 | 2008 | 674 | 0.140 |
Why?
|
| Dosage Forms | 1 | 2015 | 7 | 0.140 |
Why?
|
| Forecasting | 1 | 2017 | 304 | 0.140 |
Why?
|
| Barium Sulfate | 2 | 2006 | 43 | 0.140 |
Why?
|
| Integrins | 1 | 2016 | 76 | 0.140 |
Why?
|
| Health Status | 1 | 2018 | 360 | 0.140 |
Why?
|
| Genome, Bacterial | 1 | 2016 | 139 | 0.140 |
Why?
|
| Dehydration | 1 | 2015 | 18 | 0.140 |
Why?
|
| Ethics, Research | 1 | 2016 | 52 | 0.140 |
Why?
|
| Intraabdominal Infections | 1 | 2015 | 10 | 0.130 |
Why?
|
| Anus Diseases | 1 | 2015 | 14 | 0.130 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2016 | 88 | 0.130 |
Why?
|
| JC Virus | 1 | 2015 | 5 | 0.130 |
Why?
|
| Hydrocortisone | 1 | 2017 | 298 | 0.130 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2015 | 13 | 0.130 |
Why?
|
| Double-Balloon Enteroscopy | 1 | 2015 | 11 | 0.130 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 184 | 0.130 |
Why?
|
| Spectrum Analysis | 1 | 2015 | 118 | 0.130 |
Why?
|
| Interleukin-10 | 1 | 2016 | 149 | 0.130 |
Why?
|
| Communicable Diseases | 1 | 2016 | 63 | 0.130 |
Why?
|
| Physician's Role | 1 | 2017 | 179 | 0.130 |
Why?
|
| Dysbiosis | 1 | 2016 | 70 | 0.130 |
Why?
|
| Life Style | 2 | 2022 | 189 | 0.130 |
Why?
|
| Salvage Therapy | 2 | 2014 | 233 | 0.130 |
Why?
|
| Disability Evaluation | 2 | 2020 | 136 | 0.130 |
Why?
|
| ErbB Receptors | 1 | 2018 | 485 | 0.130 |
Why?
|
| Cladribine | 1 | 2014 | 35 | 0.130 |
Why?
|
| Catheters | 1 | 2015 | 74 | 0.130 |
Why?
|
| Discriminant Analysis | 2 | 2013 | 66 | 0.130 |
Why?
|
| DNA Methylation | 1 | 2019 | 628 | 0.130 |
Why?
|
| Antigens, CD1 | 1 | 2014 | 35 | 0.130 |
Why?
|
| Immunotherapy | 1 | 2020 | 629 | 0.130 |
Why?
|
| Intestinal Diseases | 1 | 2015 | 79 | 0.130 |
Why?
|
| Coloring Agents | 1 | 2014 | 64 | 0.130 |
Why?
|
| Intestinal Polyps | 2 | 2021 | 26 | 0.120 |
Why?
|
| Delphi Technique | 3 | 2021 | 80 | 0.120 |
Why?
|
| Host-Pathogen Interactions | 1 | 2016 | 231 | 0.120 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2014 | 23 | 0.120 |
Why?
|
| Epidemiologic Methods | 2 | 2011 | 59 | 0.120 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 295 | 0.120 |
Why?
|
| History, 18th Century | 1 | 2014 | 23 | 0.120 |
Why?
|
| Mentors | 1 | 2015 | 76 | 0.120 |
Why?
|
| Integrin alpha4 | 1 | 2013 | 11 | 0.120 |
Why?
|
| History, 19th Century | 1 | 2014 | 59 | 0.120 |
Why?
|
| Patient Readmission | 1 | 2017 | 329 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 1373 | 0.120 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2014 | 138 | 0.120 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2013 | 18 | 0.120 |
Why?
|
| Subarachnoid Space | 1 | 2013 | 17 | 0.110 |
Why?
|
| Hematoma, Subdural | 1 | 2013 | 23 | 0.110 |
Why?
|
| Snoring | 1 | 2012 | 12 | 0.110 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2008 | 100 | 0.110 |
Why?
|
| Serum | 1 | 2012 | 25 | 0.110 |
Why?
|
| Transcriptome | 1 | 2017 | 580 | 0.110 |
Why?
|
| Antimetabolites | 1 | 2011 | 24 | 0.100 |
Why?
|
| DNA, Neoplasm | 1 | 2013 | 265 | 0.100 |
Why?
|
| Lymphogranuloma Venereum | 1 | 2011 | 1 | 0.100 |
Why?
|
| Data Collection | 3 | 2009 | 372 | 0.100 |
Why?
|
| Hand-Assisted Laparoscopy | 1 | 2011 | 1 | 0.100 |
Why?
|
| Gonorrhea | 1 | 2011 | 18 | 0.100 |
Why?
|
| Chlamydia Infections | 1 | 2011 | 25 | 0.100 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2012 | 103 | 0.100 |
Why?
|
| Quality Indicators, Health Care | 1 | 2013 | 144 | 0.100 |
Why?
|
| Virus Latency | 1 | 2011 | 33 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2021 | 1004 | 0.100 |
Why?
|
| Syphilis | 1 | 2011 | 27 | 0.100 |
Why?
|
| Proto-Oncogenes | 1 | 2011 | 61 | 0.100 |
Why?
|
| Nicotinic Agonists | 1 | 2012 | 72 | 0.100 |
Why?
|
| Diffusion | 1 | 2011 | 93 | 0.100 |
Why?
|
| Analgesics, Opioid | 1 | 2015 | 413 | 0.100 |
Why?
|
| Tobacco Use Disorder | 1 | 2012 | 108 | 0.100 |
Why?
|
| Guideline Adherence | 1 | 2012 | 223 | 0.100 |
Why?
|
| Review Literature as Topic | 2 | 2023 | 21 | 0.100 |
Why?
|
| Pilot Projects | 4 | 2009 | 839 | 0.100 |
Why?
|
| Sentinel Surveillance | 1 | 2010 | 23 | 0.100 |
Why?
|
| Simplexvirus | 1 | 2011 | 151 | 0.090 |
Why?
|
| Eating | 1 | 2011 | 166 | 0.090 |
Why?
|
| Methyltransferases | 1 | 2011 | 182 | 0.090 |
Why?
|
| ROC Curve | 2 | 2011 | 752 | 0.090 |
Why?
|
| Area Under Curve | 1 | 2011 | 334 | 0.090 |
Why?
|
| Probiotics | 1 | 2011 | 81 | 0.090 |
Why?
|
| Thromboembolism | 1 | 2011 | 119 | 0.090 |
Why?
|
| Nicotine | 1 | 2012 | 194 | 0.090 |
Why?
|
| Herpes Simplex | 1 | 2011 | 202 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2011 | 272 | 0.090 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2023 | 166 | 0.090 |
Why?
|
| Absenteeism | 1 | 2009 | 9 | 0.090 |
Why?
|
| Genetic Variation | 1 | 2016 | 1351 | 0.090 |
Why?
|
| Enema | 2 | 2006 | 37 | 0.090 |
Why?
|
| Patient Preference | 1 | 2010 | 105 | 0.090 |
Why?
|
| Pregnancy | 5 | 2020 | 2894 | 0.090 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2009 | 60 | 0.090 |
Why?
|
| Hospital Mortality | 2 | 2021 | 349 | 0.090 |
Why?
|
| Family Health | 1 | 2009 | 162 | 0.090 |
Why?
|
| Terrorism | 1 | 2009 | 9 | 0.090 |
Why?
|
| Publication Bias | 1 | 2009 | 13 | 0.090 |
Why?
|
| Migraine Disorders | 1 | 2009 | 40 | 0.090 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2011 | 663 | 0.090 |
Why?
|
| Motivation | 1 | 2012 | 287 | 0.090 |
Why?
|
| Health Education | 1 | 2009 | 101 | 0.090 |
Why?
|
| Adenomatous Polyps | 1 | 2008 | 11 | 0.080 |
Why?
|
| False Positive Reactions | 2 | 2006 | 216 | 0.080 |
Why?
|
| Adaptation, Psychological | 1 | 2009 | 157 | 0.080 |
Why?
|
| Health Surveys | 1 | 2009 | 239 | 0.080 |
Why?
|
| Postoperative Period | 2 | 2021 | 303 | 0.080 |
Why?
|
| Preoperative Period | 2 | 2019 | 91 | 0.080 |
Why?
|
| Capsule Endoscopes | 1 | 2008 | 5 | 0.080 |
Why?
|
| Capsules | 1 | 2008 | 38 | 0.080 |
Why?
|
| Mice | 7 | 2020 | 11352 | 0.080 |
Why?
|
| Feasibility Studies | 2 | 2009 | 751 | 0.080 |
Why?
|
| Survival Rate | 2 | 2011 | 1863 | 0.080 |
Why?
|
| Gadolinium DTPA | 1 | 2009 | 261 | 0.080 |
Why?
|
| Homosexuality, Male | 1 | 2011 | 298 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 364 | 0.080 |
Why?
|
| Mutation | 2 | 2019 | 3968 | 0.080 |
Why?
|
| Angiotensin II | 2 | 2019 | 94 | 0.080 |
Why?
|
| Radiography | 1 | 2009 | 813 | 0.080 |
Why?
|
| Cattle | 1 | 2008 | 376 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2011 | 574 | 0.080 |
Why?
|
| Decision Making | 2 | 2022 | 642 | 0.070 |
Why?
|
| Pathology, Clinical | 1 | 2006 | 33 | 0.070 |
Why?
|
| Biopsy, Needle | 1 | 2007 | 235 | 0.070 |
Why?
|
| London | 1 | 2006 | 16 | 0.070 |
Why?
|
| Fatal Outcome | 1 | 2007 | 293 | 0.070 |
Why?
|
| Terminology as Topic | 1 | 2008 | 217 | 0.070 |
Why?
|
| Single-Blind Method | 1 | 2006 | 153 | 0.070 |
Why?
|
| Minnesota | 1 | 2006 | 46 | 0.070 |
Why?
|
| Molecular Biology | 1 | 2006 | 89 | 0.070 |
Why?
|
| Gastrointestinal Diseases | 1 | 2007 | 146 | 0.070 |
Why?
|
| Nod2 Signaling Adaptor Protein | 1 | 2005 | 13 | 0.070 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2005 | 41 | 0.070 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 429 | 0.070 |
Why?
|
| Short Bowel Syndrome | 1 | 2005 | 37 | 0.060 |
Why?
|
| Abdominal Abscess | 1 | 2004 | 22 | 0.060 |
Why?
|
| Needs Assessment | 1 | 2005 | 154 | 0.060 |
Why?
|
| Radiographic Image Enhancement | 1 | 2006 | 462 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2008 | 469 | 0.060 |
Why?
|
| Living Donors | 2 | 2017 | 339 | 0.060 |
Why?
|
| Hong Kong | 1 | 2023 | 45 | 0.060 |
Why?
|
| New York City | 2 | 2020 | 59 | 0.060 |
Why?
|
| Biological Factors | 1 | 2023 | 18 | 0.060 |
Why?
|
| Credentialing | 1 | 2023 | 13 | 0.060 |
Why?
|
| Signal Transduction | 3 | 2019 | 3241 | 0.060 |
Why?
|
| Enteral Nutrition | 1 | 2023 | 102 | 0.060 |
Why?
|
| Medical Futility | 1 | 2003 | 28 | 0.060 |
Why?
|
| Ethics, Clinical | 1 | 2003 | 48 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 159 | 0.050 |
Why?
|
| Pelvis | 1 | 2023 | 95 | 0.050 |
Why?
|
| Procarbazine | 2 | 2012 | 40 | 0.050 |
Why?
|
| Platinum Compounds | 2 | 2012 | 31 | 0.050 |
Why?
|
| Asia | 1 | 2022 | 95 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2022 | 76 | 0.050 |
Why?
|
| Amino Acids | 1 | 2023 | 252 | 0.050 |
Why?
|
| Models, Biological | 1 | 2009 | 1749 | 0.050 |
Why?
|
| Cutaneous Fistula | 1 | 2021 | 11 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2005 | 408 | 0.050 |
Why?
|
| China | 1 | 2022 | 228 | 0.050 |
Why?
|
| Women, Working | 1 | 2021 | 7 | 0.050 |
Why?
|
| Canada | 2 | 2012 | 204 | 0.050 |
Why?
|
| Rheumatic Diseases | 1 | 2022 | 20 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2008 | 1196 | 0.050 |
Why?
|
| Gastrectomy | 1 | 2002 | 68 | 0.050 |
Why?
|
| Education, Medical | 2 | 2021 | 233 | 0.050 |
Why?
|
| Eye Diseases | 1 | 2022 | 53 | 0.050 |
Why?
|
| Asthma | 1 | 2009 | 955 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2022 | 78 | 0.050 |
Why?
|
| Fissure in Ano | 1 | 2001 | 3 | 0.050 |
Why?
|
| Employment | 1 | 2021 | 52 | 0.050 |
Why?
|
| Efficiency | 1 | 2021 | 40 | 0.050 |
Why?
|
| Adolescent Development | 1 | 2021 | 18 | 0.050 |
Why?
|
| New York | 1 | 2021 | 69 | 0.050 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2021 | 13 | 0.050 |
Why?
|
| Hospitals, Teaching | 1 | 2001 | 115 | 0.050 |
Why?
|
| Nitroglycerin | 1 | 2001 | 22 | 0.050 |
Why?
|
| Mass Vaccination | 1 | 2020 | 8 | 0.050 |
Why?
|
| Equipment Design | 2 | 2015 | 406 | 0.050 |
Why?
|
| Mental Health Services | 1 | 2021 | 48 | 0.050 |
Why?
|
| Immunomodulation | 1 | 2021 | 55 | 0.050 |
Why?
|
| Malabsorption Syndromes | 1 | 2000 | 21 | 0.050 |
Why?
|
| Minority Groups | 1 | 2022 | 137 | 0.050 |
Why?
|
| Physicians, Women | 1 | 2021 | 53 | 0.050 |
Why?
|
| Medical Staff, Hospital | 1 | 2001 | 107 | 0.050 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2000 | 39 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2021 | 98 | 0.050 |
Why?
|
| Sigmoidoscopy | 1 | 2020 | 36 | 0.050 |
Why?
|
| Critical Pathways | 1 | 2020 | 35 | 0.050 |
Why?
|
| Hospitals, Urban | 1 | 2020 | 54 | 0.050 |
Why?
|
| Anti-Infective Agents | 1 | 2021 | 89 | 0.050 |
Why?
|
| Teaching | 1 | 2001 | 147 | 0.050 |
Why?
|
| Massachusetts | 1 | 2020 | 33 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 376 | 0.050 |
Why?
|
| Vasodilator Agents | 1 | 2001 | 152 | 0.050 |
Why?
|
| Breast Implantation | 1 | 2020 | 12 | 0.050 |
Why?
|
| Skin Diseases | 1 | 2022 | 166 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2022 | 927 | 0.050 |
Why?
|
| World Health Organization | 1 | 2020 | 103 | 0.050 |
Why?
|
| Diet | 1 | 2023 | 443 | 0.050 |
Why?
|
| Microvessels | 1 | 2020 | 70 | 0.040 |
Why?
|
| France | 1 | 2019 | 47 | 0.040 |
Why?
|
| Pneumonectomy | 1 | 2002 | 196 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2020 | 106 | 0.040 |
Why?
|
| Homeless Youth | 1 | 1999 | 2 | 0.040 |
Why?
|
| Risk Adjustment | 1 | 2019 | 39 | 0.040 |
Why?
|
| Primary Health Care | 2 | 2013 | 339 | 0.040 |
Why?
|
| Drug Recalls | 1 | 2019 | 13 | 0.040 |
Why?
|
| Seasons | 1 | 2020 | 223 | 0.040 |
Why?
|
| General Surgery | 1 | 2002 | 229 | 0.040 |
Why?
|
| STAT1 Transcription Factor | 1 | 2019 | 52 | 0.040 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2019 | 40 | 0.040 |
Why?
|
| Child Development | 1 | 2021 | 163 | 0.040 |
Why?
|
| Blue Cross Blue Shield Insurance Plans | 1 | 2018 | 3 | 0.040 |
Why?
|
| Image Enhancement | 2 | 2009 | 563 | 0.040 |
Why?
|
| Janus Kinase 2 | 1 | 2019 | 57 | 0.040 |
Why?
|
| Tissue Expansion Devices | 1 | 2018 | 8 | 0.040 |
Why?
|
| Nurses | 1 | 2019 | 40 | 0.040 |
Why?
|
| Affective Symptoms | 1 | 1999 | 47 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2019 | 78 | 0.040 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2002 | 466 | 0.040 |
Why?
|
| Antipsychotic Agents | 1 | 2020 | 123 | 0.040 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2019 | 51 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 331 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 2438 | 0.040 |
Why?
|
| Risk Management | 1 | 2018 | 43 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 879 | 0.040 |
Why?
|
| Liability, Legal | 1 | 2018 | 32 | 0.040 |
Why?
|
| Prednisolone | 1 | 2018 | 41 | 0.040 |
Why?
|
| Placebo Effect | 1 | 2018 | 31 | 0.040 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 154 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2018 | 244 | 0.040 |
Why?
|
| Mastectomy | 1 | 2020 | 243 | 0.040 |
Why?
|
| Research | 1 | 2019 | 253 | 0.040 |
Why?
|
| Therapeutic Human Experimentation | 1 | 1997 | 20 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 1047 | 0.040 |
Why?
|
| Drug Labeling | 1 | 2017 | 41 | 0.040 |
Why?
|
| Central Nervous System Stimulants | 1 | 2020 | 216 | 0.040 |
Why?
|
| HCT116 Cells | 1 | 2017 | 151 | 0.040 |
Why?
|
| Medicaid | 1 | 2020 | 217 | 0.040 |
Why?
|
| Fibrosis | 1 | 2018 | 203 | 0.040 |
Why?
|
| Medical Overuse | 1 | 2017 | 36 | 0.040 |
Why?
|
| Cognition Disorders | 1 | 1999 | 236 | 0.040 |
Why?
|
| Office Visits | 1 | 2017 | 44 | 0.040 |
Why?
|
| Colon, Sigmoid | 1 | 2016 | 6 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 381 | 0.040 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2016 | 21 | 0.040 |
Why?
|
| Hydralazine | 1 | 2016 | 20 | 0.040 |
Why?
|
| Fumarates | 1 | 2016 | 26 | 0.040 |
Why?
|
| Bacteroides fragilis | 1 | 2016 | 42 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2019 | 1106 | 0.040 |
Why?
|
| Losartan | 1 | 2016 | 42 | 0.040 |
Why?
|
| Occludin | 1 | 2016 | 66 | 0.040 |
Why?
|
| Sex Factors | 2 | 2015 | 1054 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2017 | 236 | 0.040 |
Why?
|
| Interleukin-8 | 1 | 2016 | 86 | 0.040 |
Why?
|
| Amides | 1 | 2016 | 60 | 0.040 |
Why?
|
| Social Perception | 1 | 2017 | 95 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2020 | 510 | 0.040 |
Why?
|
| Medicare | 1 | 2020 | 410 | 0.030 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2016 | 70 | 0.030 |
Why?
|
| Zeolites | 1 | 1995 | 4 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2017 | 256 | 0.030 |
Why?
|
| Dinoprostone | 1 | 2015 | 69 | 0.030 |
Why?
|
| Digestive System | 1 | 1995 | 42 | 0.030 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2016 | 90 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 458 | 0.030 |
Why?
|
| Embryonic and Fetal Development | 1 | 1995 | 72 | 0.030 |
Why?
|
| Liver Abscess, Amebic | 1 | 1995 | 1 | 0.030 |
Why?
|
| Entamoeba histolytica | 1 | 1995 | 3 | 0.030 |
Why?
|
| Entamoebiasis | 1 | 1995 | 3 | 0.030 |
Why?
|
| Cadherins | 1 | 2016 | 151 | 0.030 |
Why?
|
| Seroepidemiologic Studies | 1 | 2015 | 55 | 0.030 |
Why?
|
| Receptors, Calcitriol | 1 | 2016 | 129 | 0.030 |
Why?
|
| Gadolinium | 1 | 1995 | 103 | 0.030 |
Why?
|
| Cysteine Endopeptidases | 1 | 1995 | 87 | 0.030 |
Why?
|
| Sacroiliitis | 1 | 2014 | 3 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 426 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2016 | 458 | 0.030 |
Why?
|
| Glucuronosyltransferase | 1 | 2015 | 184 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 1996 | 353 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 853 | 0.030 |
Why?
|
| Group Processes | 1 | 2013 | 31 | 0.030 |
Why?
|
| Tissue and Organ Procurement | 1 | 1997 | 311 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2013 | 290 | 0.030 |
Why?
|
| Craniocerebral Trauma | 1 | 2013 | 52 | 0.030 |
Why?
|
| Fetal Blood | 1 | 2012 | 90 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 1540 | 0.030 |
Why?
|
| Child Abuse | 1 | 2013 | 78 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2016 | 669 | 0.030 |
Why?
|
| Phylogeny | 1 | 2017 | 1137 | 0.030 |
Why?
|
| Denmark | 1 | 2011 | 15 | 0.030 |
Why?
|
| Preventive Medicine | 1 | 2010 | 17 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2011 | 173 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2011 | 307 | 0.020 |
Why?
|
| Genotype | 1 | 2015 | 1851 | 0.020 |
Why?
|
| Antineoplastic Agents | 2 | 2012 | 2360 | 0.020 |
Why?
|
| Age Distribution | 1 | 2011 | 204 | 0.020 |
Why?
|
| Patient Safety | 1 | 2013 | 212 | 0.020 |
Why?
|
| Kidney Transplantation | 1 | 1997 | 849 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 273 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 1996 | 736 | 0.020 |
Why?
|
| Selenium | 1 | 1989 | 44 | 0.020 |
Why?
|
| Apoptosis | 1 | 2016 | 1683 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 504 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 782 | 0.020 |
Why?
|
| Human Rights Abuses | 1 | 2009 | 2 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 3092 | 0.020 |
Why?
|
| Israel | 1 | 2009 | 55 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1989 | 78 | 0.020 |
Why?
|
| Arabs | 1 | 2009 | 17 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2012 | 319 | 0.020 |
Why?
|
| Claudin-1 | 1 | 2008 | 17 | 0.020 |
Why?
|
| Claudins | 1 | 2008 | 33 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 2011 | 222 | 0.020 |
Why?
|
| Myocardium | 1 | 1989 | 529 | 0.020 |
Why?
|
| beta Catenin | 1 | 2008 | 251 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 2903 | 0.020 |
Why?
|
| Phenylhydrazines | 1 | 2005 | 10 | 0.020 |
Why?
|
| Pneumoradiography | 1 | 2005 | 3 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2011 | 1981 | 0.020 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2004 | 70 | 0.020 |
Why?
|
| Primary Prevention | 1 | 2005 | 85 | 0.020 |
Why?
|
| Mice, SCID | 2 | 1995 | 252 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2009 | 1078 | 0.020 |
Why?
|
| Radiation Injuries | 1 | 2005 | 155 | 0.020 |
Why?
|
| Fever | 1 | 2004 | 125 | 0.010 |
Why?
|
| Drainage | 1 | 2004 | 157 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 1998 | 1204 | 0.010 |
Why?
|
| Ointments | 1 | 2001 | 12 | 0.010 |
Why?
|
| Xylose | 1 | 2000 | 23 | 0.010 |
Why?
|
| Administration, Topical | 1 | 2001 | 95 | 0.010 |
Why?
|
| Breath Tests | 1 | 2000 | 55 | 0.010 |
Why?
|
| Workload | 1 | 2001 | 128 | 0.010 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2000 | 62 | 0.010 |
Why?
|
| Medical History Taking | 1 | 2000 | 80 | 0.010 |
Why?
|
| Intelligence | 1 | 1999 | 71 | 0.010 |
Why?
|
| Psychological Tests | 1 | 1999 | 91 | 0.010 |
Why?
|
| Child Behavior Disorders | 1 | 1999 | 76 | 0.010 |
Why?
|
| Educational Status | 1 | 1999 | 188 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2002 | 579 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 1999 | 319 | 0.010 |
Why?
|
| Blood Group Incompatibility | 1 | 1997 | 18 | 0.010 |
Why?
|
| Public Opinion | 1 | 1997 | 43 | 0.010 |
Why?
|
| Peer Review, Research | 1 | 1997 | 36 | 0.010 |
Why?
|
| Confidentiality | 1 | 1997 | 78 | 0.010 |
Why?
|
| ABO Blood-Group System | 1 | 1997 | 62 | 0.010 |
Why?
|
| von Willebrand Factor | 1 | 1996 | 37 | 0.010 |
Why?
|
| Hospitals, University | 1 | 1997 | 194 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2001 | 636 | 0.010 |
Why?
|
| Microcirculation | 1 | 1996 | 106 | 0.010 |
Why?
|
| Transplantation, Isogeneic | 1 | 1995 | 39 | 0.010 |
Why?
|
| Immunologic Techniques | 1 | 1995 | 27 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1995 | 307 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1995 | 370 | 0.010 |
Why?
|
| Informed Consent | 1 | 1997 | 266 | 0.010 |
Why?
|
| Dogs | 1 | 1995 | 685 | 0.010 |
Why?
|
| Phantoms, Imaging | 1 | 1995 | 429 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 1995 | 724 | 0.010 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1989 | 97 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1995 | 1195 | 0.010 |
Why?
|